BTK inhibitor 17

• CAT Number: I035318
• CAS Number: 1858206-76-4
• Molecular Formula: C25H24N6O3
• Molecular Weight: 456.50
• Purity: ≥95%
• Synonyms: 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]-6H-pyrazolo[3,4-d]pyridazin-7-one
• InChI: InChI=1S/C25H24N6O3/c1-2-20(32)30-14-6-7-17(15-30)31-23-21(24(26)27-28-25(23)33)22(29-31)16-10-12-19(13-11-16)34-18-8-4-3-5-9-18/h2-5,8-13,17H,1,6-7,14-15H2,(H2,26,27)(H,28,33)/t17-/m1/s1
• InChIKey: QUYXPVXTKPTPCA-QGZVFWFLSA-N
• SMILES: C=CC(=O)N1CCCC(C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NNC3=O)N

BTK inhibitor 17 (Cat No.: I035318) is a potent, selective small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), a key signaling enzyme in the B-cell receptor (BCR) pathway that regulates B-cell development, activation, and survival. By blocking BTK activity, it suppresses downstream signaling cascades such as NF-κB, reducing proliferation and survival of malignant or overactive B cells. BTK inhibitor 17 is used in immunology and oncology research to study B-cell–mediated disorders, including B-cell malignancies and autoimmune diseases, and to explore targeted therapeutic strategies in hematological cancers.

Reference

[1]. Xuejun Zhang, et al. Discovery and Evaluation of Pyrazolo[3,4- d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. ACS Med Chem Lett. 2019 Dec 11;11(10):1863-1868.
[Content Brief]